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Abstract
Menkes disease (MD) is caused by mutations in the ATP7A gene. We describe 33 novel splice site mutations detected in
patients with MD or the milder phenotypic form, Occipital Horn Syndrome. We review these 33 mutations together with 28
previously published splice site mutations. We investigate 12 mutations for their effect on the mRNA transcript in vivo.
Transcriptional data from another 16 mutations were collected from the literature. The theoretical consequences of splice
site mutations, predicted with the bioinformatics tool Human Splice Finder, were investigated and evaluated in relation to in
vivo results. Ninety-six percent of the mutations identified in 45 patients with classical MD were predicted to have a
significant effect on splicing, which concurs with the absence of any detectable wild-type transcript in all 19 patients
investigated in vivo. Sixty-seven percent of the mutations identified in 12 patients with milder phenotypes were predicted
to have no significant effect on splicing, which concurs with the presence of wild-type transcript in 7 out of 9 patients
investigated in vivo. Both the in silico predictions and the in vivo results support the hypothesis previously suggested by us
and others, that the presence of some wild-type transcript is correlated to a milder phenotype.
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Introduction
Menkes disease (MD) is an X-linked, multisystemic lethal
disorder of copper metabolism caused by mutations in the ATP7A
gene. The severe classical form of MD is characterised by
progressive neurodegeneration, connective tissue abnormalities,
distinctive ‘‘kinky’’ hair and ultimately death in early childhood.
Though most patients (90–95%) exhibit the severe clinical course,
there are various milder atypical forms with longer survival of the
affected patients (atypical MD). The Occipital Horn Syndrome
(OHS), mainly characterized by connective tissue manifestations is
the mildest form [1].
A broad spectrum of ATP7A mutations (from single amino acid
substitutions to large deletions and chromosome aberrations) has
been identified in patients with classical or one of the milder MD
forms [2]. Approximately 22% of these ATP7A mutations are
splice site mutations [2].
Splice site mutations are DNA sequence changes that alter or
abolish correct mRNA splicing during the process of precursor
mRNA maturation. Splice site mutations can result in the
complete skipping of one or more exons, retention of introns,
creation of a pseudo-exon, or activation of a cryptic splice site
within an exon or an intron [3]. The resulting transcript may
either be in-frame or out-of-frame. An in-frame transcript may
lead to the production of a functional or partially functional
protein, whereas out-of-frame transcripts are likely to cause the
formation of a premature termination codon and subsequent rapid
nonsense–mediated mRNA decay [4,5]. Some splice site muta-
tions do not abolish the wild-type transcript expression completely,
which may lead to less severe phenotypes [6,7,8].
This study presents a comprehensive overview of 61 splice site
mutations in the ATP7A gene including 33 novel mutations,
identified in patients with classical MD, atypical MD or OHS.
Studies of splice site mutations are highly relevant in order to
identify a correlation between the effects of splice site mutations
and patient phenotypes, to enable a prediction of the severity of
the disease, and to design therapies. It has been proposed that MD
patients might especially benefit from early copper therapy when
some functional ATP7A protein is present [9]. We investigated the
effect of 12 mutations in vivo, and 61 mutations with the
bioinformatics tool, Human Splicing Finder (HSF). We compared
the in silico predictions with in vivo results and with the observed
phenotypes of the patients.
Materials and Methods
Samples and mutation detection
The 33 novel splice site mutations were found in a cohort of
MD patients who were referred to the Kennedy Center for
molecular and/or biochemical diagnosis. Mutations were identi-
fied by PCR amplification and direct sequencing of the 23 exons
using an ABI3130XL sequencer (Applied Biosystems, Foster, CA).
Transcript analysis
Fibroblast cell cultures obtained from patient-skin biopsies were
grown in a 1:1 mixture of RPMI 1640 with 20 mM HEPES and a
nutrient mixture of F-10 Hams medium, supplemented with 7.5%
Amnio Max (Life Technologies), C100 supplement, 4% fetal calf
serum, penicillin, and streptomycin. RNA was isolated with
RNeasy (QIAgen, Bothell, WA), and single-stranded cDNA was
synthesized with the High-Capacity cDNA Archive Kit in
accordance with the manufacturers instructions (Applied Biosys-
tems, Foster, CA). To investigate the effect of selected splice site
mutations, RT-PCR was carried out with primers specific for
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e18599Table 1. In silico splice site predictions.
Case (ID)
Pheno-






and CV, if potential
cryptic splice site is used
Known transcripts
from mutant sequences
1 (93220) C c.1707+1G.A
(IVS6, DS)[ 1 4 ]
82.62 55.79 232.48 217: 72.02/+4: 85.11/+16: 70.01/
+50: 91.34/+55: 71.12/+86: 87.61
NNo wt transcript [14]; NCryptic
splice site leading to 4 bp elongation
of exon 6 (frameshift) [14]; NExon
6 skipping (frameshift) [14]; NExon
6 and 7 skipping (frameshift)[14]
2 (91209) C c.1707+5G.A
(IVS6, DS)[ 1 4 ]
82.62 70.46 214.72 217: 72.02/+16: 70.1/+50: 91.34/
+55: 71.12/+86: 87.61
NNo wt transcript [14]; NCryptic
splice site leading to 50 bp
elongation of exon 6 (frameshift)
[14]; NExon 6 skipping (frameshift) [14];
NExon 6 and 7 skipping (frameshift) [14]
3 (94268) O c.1707+6_+9del
TAAG (IVS6, DS)
[13,14]





4 (93279) C c.1708-1G.C*
(IVS6, AS)
89.36 60.42 232.39 25: 75.83 (+4.82)/240: 70.03/
262: 77.13/264: 70.05/+23: 78.93
5 (9224) C c.1870-1G.C
(IVS7, AS) [24]
75.73 46.79 238.22 22: 91.28 (+12.71)/27: 80.24 (+3.27)/
216: 74.05/230: 78.15/233: 75.45/
243: 73.38/255: 72.14/+32: 84.74/
+62: 71.02
NNo wt transcipt*; NCryptic splice
site leading to a 2 bp deletion
of exon 8 (frameshift)*
6 (93271) C c.1870-2A.T*
(IVS7, AS)
75.73 46.79 238.22 22: 80.88/27: 80.91 (+4.14)/
216: 74.05/230: 78.15/233: 75.45/
243: 73.38/255: 72.14/+32: 84.74/
+62: 71.02
NNo wt transcript*; NCryptic splice site
leading to a 7 bp deletion of exon 8
(frameshift)*; NCryptic splice site leading
to a 2 bp deletion of exon 8
(frameshift)*
7 (95222) C c.1946+1G.A*
(IVS8, DS)
83.72 56.88 232.05 231: 72.38/239: 86.07/
253: 74.15/+16:78.3/+65: 84.11
8 (91266) C c.1946+1G.C
(IVS8, DS)[ 2 4 ]
83.72 56.88 232.05 231: 72.38/239: 86.07/253:
74.15/+16: 78.3/+65: 84.11
NNo wt transcript*; NExon
8 skipping (frameshift)*
9 (93237) C c.1946+1G.T*
(IVS8, DS)
83.72 56.88 232.05 231: 72.38/239: 86.07/
253: 74.15/+16:78.3/+65: 84.11
NNo wt transcript*; NExon
8 skipping (frameshift)*
10 (91267) C c.1946+2T.C
(IVS8, DS)[ 1 5 ]
83.72 56.88 232.05 231: 72.38/239: 86.07/
253: 74.15/+16: 78.3/+65: 84.11
NNo wt transcript[15]; NExon
8 skipping (frameshift)[15]
11 (94235) C c.1946+2_+3del
TA (IVS8, DS)[ 2 4 ]
83.72 32.58 261.08 - NNo wt transcript*; NExon
8 skipping (frameshift)*
12 (94230) C c.1946+5G.A
(IVS8, DS)[ 2 4 ]
83.72 71.55 214.53 231: 72.38/239: 86.07/
253: 74.15/+16: 78.3/+65: 84.11
NNo wt transcript*; NExon
8 skipping (frameshift)*
13 (9529) C c.1946+5G.C
(IVS8, DS)[ 2 4 ]
83.72 71.7 214.35 231: 72.38/239: 86.07/
253: 74.15/+16: 78.3/+65: 84.11
NNo wt transcript *; NExon
8 skipping (frameshift)*
14 (91226) C c.1946+6T.G
(IVS8, DS)[ 2 4 ]
83.72 81.78 22.31 231: 72.38/239: 86.07/
253: 74.15/+16: 78.3/+65: 84.11
NNo wt transcript*; NExon
8 skipping (frameshift)*
15 (92288) C c.1947-1G.T*
(IVS8,AS)
78.85 49.91 236.71 26: 71.53 (+3.17)/224: 79.21/
+45: 80.72/+61: 74.54/+68: 82.15
16 (92285) A c.1947-5_-1
dupATAAG
(IVS8,AS) [15]
78.85 68.06 213.68 224: 79.21/+5: 78.85 NNo wt transcript [15]; NCryptic
splice site leading to a 5 bp
elongation of exon 9 (frameshift) [15];
NExon 8 skipping and cryptic splice
site use in exon 9 (as described above)
(in-frame) [15]
17 (94247) C c.2171A.C*
(E9,DS)
Gln724Pro
73.16 68.41 26.49 216: 73.46/+4: 76.1/+11: 76.23/
+59: 71.12/+64: 73.05/+89: 80.17
18 (92263) C c.2172G.T
(E9, DS)[ 9 ]
Gln724His
73.16 62.3 214.85 216: 73.46/+4: 76.1/+11: 76.23/
+59: 71.12/+64: 73.05/+89: 80.17
NNo wt transcript[9]; NExon 9 skipping
(frameshift)[9]; NExon 8 and 9 skipping
(in-frame)[9]; NExon 9 and 10 skipping
(frameshift)[9]; NExon 8 to 10 skipping
(in-frame)[9]; NExon 9 to 10 skipping
(in-frame)[9]
19 (96281) - c.2172+1G.A*
(IVS9, DS)
73.16 46.33 236.68 216: 73.46/+4: 75.14/+11: 76.23/
+59: 71.12/+64: 73.05/+89: 80.17
20 (96202) C c.2172+5G.C
(IVS9, DS)[ 2 0 ]
76.13 61.15 216.42 216: 73.46/+11:76.23/
+59: 71.23/+64: 73.05/+89: 80.17
N No wt transcript[20]; N Exon 9 skipping
(frameshift)[20]; N Exon 8 and 9 skipping
(in-frame)[20]
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Case (ID)
Pheno-






and CV, if potential
cryptic splice site is used
Known transcripts
from mutant sequences
21 (95237) A c.2172+6T.G
(IVS9, DS)[ 2 5 ]
73.16 71.23 22.64 216: 73.46/+11: 76.23/
+59: 71.23/+64: 73.05/+89: 80.17
NWt transcript present[25];
NExon 9 skipping[25]




23 (93217) C c.2173-1G.C*
(IVS9, AS)
84.92 55.98 234.08 210: 80.46 (+2.3)/230: 91.77/
258: 73.35/+40: 81.82/
+59: 71.26/+67: 75.55
24 (92276) - c.2406G.C*
(E10, DS)
Lys802Asn
84.95 73.93 212.96 284: 72.97/+5: 85.11/
+15: 78.68/+32: 72.88/+37: 71.5
25 (94207) O c.2406+3A.T
(IVS10, DS) [16]
84.95 79.92 25.91 284: 72.97/+5: 85.11/
+15: 78.68/
+32: 72.88/+37: 71.5
NNo wt transcript[16]; NExon
10 skipping (in-frame)[16]
26 (91249) O c.2497A.G
(E11, DS)
[23] Ser833Gly
78.88 74.02 26.16 232: 71.41/266: 71.28 NWt transcript present[23];
NExon 11 skipping[23]; NCryptic
acceptor splice site activation
leading to 220 bp deletion[23]
27 (9421) C c.2498+1G.A*
(IVS11, DS)
78.88 52.04 234.02 232: 71.41/266: 71.28
28 (93242) C c.2499-1G.A*
(IVS11, AS)
83.47 54.52 234.68 25: 74.99 (+0.09)/238: 72.02/
250: 75.22/253: 72.2/259: 83.01/
262: 77.07/274: 80.01/295: 79.14/
+43: 71.15/+48: 76.56/+53: 74.64/
+55: 74.32/+68: 73.14/+85: 70.4
29 (92294) C c.2626+2T.A*
(IVS12, DS)




91.2 80.18 212.08 218: 70.02/222: 73.79 NNo wt protein expression[27]
31 (93233) C c.2627-2A.G
(IVS12, AS) [24]
93.47 64.52 230.97 25: 70.12/+43: 76.86/+71: 74.12/
+85: 82.75
32 (91247) A c.2627G.A
(E13, AS)
[27] Gly876Glu
93.47 89.31 24.45 223: 72.24/234: 76.68/
239: 80.17/262: 82.32/299: 71.17/
+43: 76.86/+71: 74.12/+85: 82.75
NWt transcript present*;
NExon 14 and 15 skipping*
33 (91214) C c.2781+1G.A*
(IVS13, DS)
87.03 60.2 230.83 263: 73.43/288: 78.11
34 (93243) C c.2916+1G.A*
(IVS14, DS)
84.38 57.55 231.8 245: 71.11/254: 82.53/+4: 74.27/
+43: 81.25/+60: 70.37
35 (9724) - c.2916+3_2916
+6delAAGT*
(IVS14, DS)
84.38 71.21 215.61 -
36 (95243) C c.2916+5G.A*
(IVS14, DS)
84.38 72.22 214.42 245: 71.11/254: 82.53/+43: 81.24/
+60: 70.37
37 (94209) O c.2917-4A.G
(IVS14, AS) [21]
87.24 87.17 20.08 211: 70.03/228: 85.47/255: 78.76/
267: 86.13/+40: 87.11/+71: 75.67
NWt transcript present[21];
NExon 15 skipping (in-frame)[21]
38 (96255) C c.3111G.T
(E15, DS)
[26] Lys1037Asn
96.71 85.84 211.24 229: 75.45/256: 73.56/260: 74.47/
268: 70.26/272: 84.8/+60: 85.64
39 (94211) O c.3111+4A.C*
(IVS15, DS)
96.71 87.91 29.1 229: 75.45/256: 73.56/260: 74.47/
268: 70.26/272: 84.8/+60: 85.64
40 (95202) C c.3112-2A.C*
(IVS15, AS)
94.41 65.47 230.66 26: 79.57 (+3.38)/224: 71.55/252: 77.66/
264: 70.27/269: 72.94/283: 73.04/289:
76.04/+35: 71.88/+46: 79.18/+70: 82.84
41 (92265) C c.3112-2A.G*
(IVS15, AS)
94.41 65.47 230.66 26: 77.03 (+0.08)/224: 71.55/252: 77.66/
264: 70.27/269: 72.94/283: 73.04/289:
76.04/+35: 71.88/+46: 79.18/+70: 82.84
42 (92244) C c.3294+1G.C*
(IVS16, DS)
79.03 52.2 233.96 250: 74.12/266: 71.59/
+41: 73.71/+71: 72.97
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to be affected by the mutation, and the flanking exons. The cDNA
fragment spanning from exon 6 to exon 9 was PCR amplified from
8 patients (cases: 5, 6, 8, 9, 11–14). The cDNA fragment spanning
from exon 12 to exon 16 was PCR amplified from patient 32. The
cDNA fragment spanning from exon 18 to exon 23 was amplified
from 3 patients (cases: 58–60). Primer sequences can be obtained
upon request. The PCR products were separated on a 1% agarose
gel. The relevant bands were purified, and sequenced using an
ABI3130XL sequencer (Applied Biosystems, Foster, CA).
Bioinformatics
We have compiled 61 ATP7A splice site mutations. All were
analysed with HSF version 2.4 [10] (http://www.umd.be/HSF/).
Only those mutations that are located in the defined splice site
consensus sequences are included here. The consensus sequences
are (C/A)AG | gt(a/g)agt and cag | G for the donor splice site and the
acceptor splice site, respectively [11]. The mutation designations
are based on ATP7A transcript ENST00000341514 from En-
sembl. A in the ATG start codon is defined as c.1. The relative
strength of the splice sites obtained from the bioinformatics tool is
Case (ID)
Pheno-






and CV, if potential
cryptic splice site is used
Known transcripts
from mutant sequences
43 C c.3293_3294del AG
(IVS16, DS)[ 1 3 ]
79.03 67.06 215.15 - NNo wt transcript[13];
NExon 16 skipping[13]
44 (96201) - c.3294+2T.C*
(IVS16, DS)
79.03 52.2 233.96 250: 74.12/266: 71.59/
+41: 73.71/+71: 72.97
45 (96272) C c.3511+1G.A*
(IVS17, DS)
87.25 60.41 230.76 254: 70.42
46 (94210) O c.3511+5G.A
(IVS17, DS)[ 2 1 ]
87.25 75.08 213.94 254: 70.42 NWt transcript present[21]; NExon 17
skipping (frameshift)[21]
47 (95278) C c.3658+1delG*
(IVS18, DS)
92.36 32.29 265.05 21: 85.44 (+106.3)
48 (95219) C c.3801+1G.T*
(IVS19, DS)
87.68 60.85 230.6 +13: 84.58/+17: 71.34
49 (93273) C c.3801+3A.C*
(IVS19, DS)
87.68 82.66 25.73 254: 79.73/+13: 86.04
50 (94294) C c.3801+4A.G*
(IVS19, DS)
87.68 79.34 29.51 +13: 84.58/+17: 71.34
51 C c.4004delG
(E20, DS) [13]
94.19 17.93 280.96 21: 99.05 (+86.96)/266: 76.34/
+28: 71.67/+48: 76.3
52 (91224) C c.4005+1G.T*
(IVS20, DS)
94.19 67.35 228.49 21: 79.92 (+50.55)/266: 76.34/
+28: 71.67/+48: 76.3
53 (92275) C c.4005+5G.A*
(IVS20, DS)
94.19 82.02 212.92 266: 76.34/+28: 71.67/
+48: 76.3
54 (96203) C c.4006-2A.G
(IVS20, AS) [15]
82.54 53.6 235.07 219: 77.51/241: 74.39/243: 73.64/
245: 72.36/249: 70.58/256: 70.86/
+35: 71.75/+37: 70.96/+41: 74.56/
+68: 77.5
NNo wt transcript[15]; NExon 21 skipping
(frameshift and premature stop
codon)[15]; NCryptic splice site in exon
21 (frameshift and premature stop
codon)[15]
55 C c.4123+1G.A
(IVS21, DS)[ 2 2 ]
86.45 59.61 231.04 222: 79.55/+4: 73.98/+38: 71.13
56 (94206) A c.4123+3A.T
(IVS21, DS)[ 2 3 ]
86.45 81.42 25.81 222: 79.55/+38: 71.13 NWt transcript present[23]; NExon 21
skipping (frameshift)[23]
57 (91284) A c.4123+5G.A*
(IVS21, DS)
86.45 74.28 214.07 222: 79.55/+38: 71.13
58 (92235) C c.4226+1G.A*
(IVS22, DS)
83.43 56.59 232.17 285: 77.51/+4: 76.3/+62: 84.93 NNo wt transcript*; NExon 22 skipping*
59 (91233) C c.4226+2T.C
(IVS22, DS)[ 2 4 ]
83.43 56.59 232.17 285: 77.51/+4: 78.28/+62: 84.93 NNo wt transcript*; NExon 22 skipping*
60 (9522) C c.4226+5G.A*
(IVS22, DS)
83.43 71.26 214.58 285: 77.51/+62: 84.93 NNo wt transcript*; NExon 22 skipping*
61 (92278) A c.4226+6T.C*
(IVS22, DS)
83.43 81.25 22.61 285: 77.51/+62: 84.93
A comprehensive overview of identified splice site mutations in donor sites (DS) and acceptor sites (AS) of the ATP7A gene. The mutations are located in exon-intron
boundaries in either the intervening sequence (IVS) or in the exon sequence (E). The various mutations lead to different MD phenotypes classified as classical MD (C),
atypical MD (A), OHS (O) or unknown (2). The mutations were analysed with the online bioinformatics tool, Human Splicing Finder (HSF), to predict the splicing signals
in wild-type and mutated DNA sequences. The strength of the splice sites is indicated by the consensus value (CV) and the CV variation (DCV). Potential cryptic splice
sites predicted with HSF are given. Effects on pre-mRNA splicing that have been identified in vivo are listed.
*Found in this study.
doi:10.1371/journal.pone.0018599.t001
Table 1. Cont.
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Splice sites with CVs higher than 80 are strong splice sites; less
strong sites have CVs that range from 70 to 80. Splice sites with
CVs of 65 to 70 are weak, as only a few of these sites are active
[10]. Hence, splice sites with CVs below 70 are herein considered
non-functional. The CV-output from HSF only indicates the
strength of the actual splice site and does not take the possible
effect of (and on) other cis-acting elements into account. The effect
of a splice site mutation does not solely depend on the CV value,
but also on the relative change in DCV. Desmet et al. (2009) [10]
emphasised that DCV reductions of at least 10% for a mutation in
any position, or of 7% for a mutation in position +4, are likely to
affect splicing.
Results
When screening the coding region of the ATP7A gene in
patients with Menkes disease or Occipital Horn Syndrome, we
identified a total of 33 novel splice site mutations. They are listed
in Table 1 together with 28 previously identified splice site
mutations. Forty-five of these mutations lead to classical MD, 6
lead to the less severe atypical MD, and 6 mutations were
identified in patients with the mildest phenotype, OHS. Only 4 of
the mutations were identified in MD patients with unknown
clinical phenotypes.
We determined the effect of the mutations on ATP7A transcript
processing in 12 patients, from whom fibroblast cultures were
available (cases: 5, 6, 8, 9, 11–14, 32, 58–60) (Figure 1). In total,
the effect on mRNA splicing in vivo is described for 28 of the 61
mutations, as the effects of the mutations on mRNA processing in
16 other cases were collected from the literature. The results are
summarised in Table 1. Most of the mutations analysed in vivo lead
to exon-skipping (cases: 3, 8–14, 18, 20, 21, 25, 32, 37, 43, 46, 56,
58–60). Other mutations lead to the use of a cryptic splice site
(cases: 5, 6) or to several different transcripts with a combination of
exon-skipping and the use of a cryptic splice site (cases: 1, 2, 16,
26, 54). The majority of the reported cases lead to the production
of out-of-frame transcripts and hence, probably to non-functional
protein. However, in some cases (cases: 3, 21, 26, 32, 37, 46, 56), a
limited amount of wild-type transcript is produced alongside the
mutant transcript. Only in two cases, leading to atypical MD and
OHS respectively (16, 25), wild-type transcript could not be
detected. No wild-type transcript was identified in any of the
classical MD cases analysed (cases: 1, 2, 5, 6, 8–14, 18, 20, 30, 43,
54, 58–60).
To explore whether a bioinformatics tool can be used to predict
the effect of the genomic mutations on mRNA processing, and
possibly the severity of the disease, we compared the experimental
results and the observed phenotypes with the predictions obtained
with the Human Splicing Finder.
The Human Splicing Finder results are listed in Table 1.
Seventy-six percent (34/45) of the classical MD cases have a splice
site CV below 70. Ninety-three percent (42/45) of the cases have a
DCV reduction over 10% (or 7% for +4 mutations) (Table 2).
Ninety-six percent of the same mutations (43/45) lead to either a
CV below 70 or a DCV reduction over 10% (or 7% for +4
mutations). Only two of the mutations among the classical MD
cases lead to both a CV above 70 and a DCV reduction below
10% (cases: 14, 49).
In contrast, among the mutations identified in the 6 atypical
MD patients and the 6 OHS patients, only four mutations (33%)
lead to a DCV reduction over 10% (or 7% for +4 mutations)
(cases: 16, 39, 46, 57). One of these mutations (16) also leads to a
splice site CV below 70 and, as expected, no detectable wild-type
transcript in the fibroblast material. In 67% of the mutations that
lead to the mild phenotypes, the splice site CVs were above 70 in
combination with DCV reductions below 10%, indicating that
these sites are active (Table 2). In agreement with this, detectable
amounts of wild-type transcript were found in 7 of the 9 analysed
patients with mild phenotypes. Only two patients (cases: 16, 25)
lacked detectable wild-type transcript.
In 15 cases (2, 12, 13, 17, 24, 30, 35, 36, 38, 39, 46, 50, 53, 57, 60) the
CV- and DCV-parameters contradicted in the prediction of activity of
the splice site. Mutations at the +5 position in particular, are responsible
for a large fraction of these cases, as they constitute half of the total
inconsistent incidences. In fact, the predictions for 8 out of 9 +5p o i n t
mutations are inconsistent. This indicates that the determination of both
the CV and the DCV is essential.
As splice site mutations may lead to the use of cryptic splice
sites, potential splice sites in the vicinity of wild-type splice sites
were identified with HSF. Most cryptic splice sites are likely to be
located +/2 100 bp on each side of the exon-intron boundary
[12]. Therefore only this area was investigated for the presence of
potential splice sites. All experimentally identified cryptic splice
sites in the patient material were among the potential splice sites
suggested by HSF.
Discussion
This study reviews disease-causing splice site mutations in
ATP7A in relation to their effect on transcript processing and
patient phenotype. Of the 57 mutations identified in patients with
known clinical phenotypes, 21% of the mutations lead to the
milder phenotypes, atypical MD or OHS (Table 2). We have
previously reported that only 9% of all MD patients display the
milder phenotypes [2]. Thus, splice site mutations relatively often
lead to the milder phenotypes when compared to ATP7A
mutations in general. This fact renders these mutations highly
interesting for further research, and makes predictions of effects on
pre-mRNA splicing, using bioinformatics tools, very relevant.
Wild-type transcript was detected in vivo in most OHS and
atypical MD cases, but not in any of the tested, classical MD cases.
We and others have previously shown that even a small amount of
wild-type protein may have a major impact on the outcome of the
disease in individuals with splice site mutations in ATP7A [13,14].
For instance, 2–5% correctly spliced ATP7A mRNA, as compared
to the level in unaffected individuals, is enough to develop the mild
phenotype, OHS [14].
Assuming that a splice site CV above 70 combined with a DCV
reduction below 10% (or 7% for +4 mutations) allow the
production of some amount of wild-type transcript, whereas a
CV below 70 combined with a DCV reduction over 10%
Figure 1. Analysis of ATP7A mRNA from patient fibroblasts. RT-
PCR was performed on mRNA extracted from 12 different patient
fibroblast cultures. The picture is obtained from three different gels
marked by space separation. Gel A) Fragment spanning the cDNA
sequence from exon 6 to exon 9; Gel B) Fragment spanning the cDNA
sequence from exon 12 to exon 16; Gel C) Fragment spanning the cDNA
sequence from exon 18 to exon 23. N=Normal, fibroblasts from
unaffected individual.
doi:10.1371/journal.pone.0018599.g001
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the mutations identified in classical MD patients are predicted to
have a significant effect on splicing with no production of wild type
transcript. However, this is only the case for 33% of the mutations
identified in patients with the milder phenotype. Overall, when
using the CV parameter in combination with the DCV parameter,
51 of 57 mutations (89%) fit the hypothesis that mild phenotypes
develop when wild-type transcript is produced, whereas classical
MD is the phenotypic outcome when no wild-type transcript is
produced (Table 2). Only, in vivo result from one case with classical
MD does not fit this hypothesis. In case 14, with a CV above 70
and a DCV reduction below 10%, we were, in contrast to the
prediction, unable to detect any wild-type transcript in vivo. There
are also two exceptions, based on in vivo results, among cases with
the mild phenotypes. In case 16, no wild-type transcript was
detected in vivo in fibroblasts with the identified mutation, which
concurs with the prediction given by HSF. The mild phenotype is
thought to be caused by the production of an in-frame transcript,
in which exon 8 is skipped and exon 9 is extended with 5 bp [15];
exon 8 encodes the region of the ATP7A-protein between the last
metal-binding domain and the first transmembrane domain. In
Case 25 with OHS phenotype: we were unable to detect any wild-
type transcript; this contradicts the prediction given by HSF. The
mild phenotype is also in this case thought to be related to the
production of a partially functional protein-variant encoded by an
in-frame transcript, which in this case lacks exon 10. The resulting
ATP7A-protein lacks transmembrane domains 3 and 4, and is
located in the endoplasmatic reticulum instead of its correct
location in the trans-Golgi network [16]. It has been proposed that
this ‘‘mis-localised’’ protein may retain some of its copper
transporting function, resulting in the less severe phenotype.
In approximately one third of the represented exon-intron
boundaries (8 of 26) the CV for one or more of the potential splice
sites identified with HSF is higher than the CV for the un-mutated
wild-type splice site. A similar observation has previously been
reported in e.g. the b-globin intron 1 [17]. In b-globin intron 1 the
authentic donor splice site is always used in the wild-type sequence,
although there is a slightly stronger cryptic splice site close by which
is only used when the wild-type splice site is mutationally weakened.
In case 2, HSF found several possible alternative donor splice
sites (217, +16, +50, +55, +86), in the vicinity of the wild-type
splice site. We have previously reported that a cryptic splice site at
position +50 is used in the mutated sequence in this patient [14].
This means that the active cryptic splice site is not the potential
splice site closest to the wild-type splice site. This concurs with
observations made by Roca and colleagues [17] who found that 26
of 61 transcripts (43%), in which cryptic splice sites were analysed,
skip the nearest potential splice site and use a site further away.
The choice of site involves a very complex interplay between
various factors, such as sequence context, available transacting
factors and secondary structure of the pre-mRNA [17,18,19].
Inconclusion, both thein silico predictionsand invivoresultssupport
the hypothesis previously suggested by us and others, that the
presence of some wild-type transcript correlates with a milder
phenotype. Notably, disease-causing mutations identified in patients
with mild phenotypes might be difficult to distinguish from benign
mutations, which do not cause disease. However, if the family history
confirms beyond any doubt, that a splice site mutation is the cause of
disease, HSF is very successful in predicting the phenotype.
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